Ruparib 300mg Tablet

About

Ruparib 300mg Tablet contains Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. This medication is indicated for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have been treated with two or more prior lines of chemotherapy. Rucaparib works by inhibiting PARP enzymes, which are crucial for DNA repair in cells. In cancer cells with existing DNA repair defects, such as BRCA mutations, PARP inhibition leads to synthetic lethality, causing the accumulation of DNA damage and subsequent cancer cell death.

This targeted therapy offers a significant advantage by specifically exploiting the vulnerabilities of BRCA-mutated cancer cells, thereby providing a more precise and effective treatment option for eligible patients with recurrent disease. It can also be used as maintenance therapy.

Uses

• Recurrent ovarian cancer (BRCA-mutated)
• Recurrent fallopian tube cancer (BRCA-mutated)
• Recurrent primary peritoneal cancer (BRCA-mutated)
• Maintenance treatment for recurrent ovarian cancer

Directions For Use

Take orally, usually twice daily, with or without food. Swallow tablets whole and do not crush or chew.

Benefits

• Effective in BRCA-mutated ovarian cancer.
• Oral administration for patient convenience.
• Offers a targeted therapy approach.
• Can be used as maintenance therapy.
• May prolong progression-free survival.
• Provides an option for patients with recurrent disease.

Side Effects

• Nausea
• Fatigue
• Vomiting
• Anemia
• Abdominal pain
• Constipation
• Dysgeusia (taste disturbance)
• Decreased appetite
• Diarrhea
• Thrombocytopenia
• Neutropenia
• Increased creatinine

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may exacerbate gastrointestinal side effects or liver strain. Use in moderation.
• Pregnancy - Contraindicated. Rucaparib can cause fetal harm. Use effective contraception during treatment and for 6 months after the last dose.
• Breastfeeding - Contraindicated. It is unknown if rucaparib is excreted in human milk; discontinue breastfeeding due to potential for serious adverse reactions.
• Liver - Use with caution in patients with hepatic impairment. Monitor liver function tests regularly.
• Kidney - Use with caution in patients with renal impairment. No specific dose adjustment for mild-moderate, but severe impairment data is limited.
• Lung - Monitor for new or worsening respiratory symptoms; interstitial lung disease has been reported with PARP inhibitors.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.